Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69
Guggenheim analyst Michael Schmidt maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and lowers the price target from $70 to $69.
An expert who liked the company still likes it, but thinks the stock price might be slightly lower. This tiny change doesn't mean the company's plans changed, so watch if other experts agree or disagree.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.